Vaccines, Subunit

• 

  Subject Areas on Research

  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. 
  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. 
  • Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. 
  • Active immunotherapy for TNF-mediated inflammation using self-assembled peptide nanofibers. 
  • Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T_H 17 responses. 
  • Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. 
  • An Engineered Biomimetic MPER Peptide Vaccine Induces Weakly HIV Neutralizing Antibodies in Mice. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. 
  • Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. 
  • Covalent complexes of antigen and alpha(2)-macroglobulin: evidence for dramatically-increased immunogenicity. 
  • Cross-reactivity of HIV vaccine responses and the microbiome. 
  • Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Enabling sublingual peptide immunization with molecular self-assemblies. 
  • Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. 
  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. 
  • HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. 
  • HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. 
  • HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. 
  • Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. 
  • Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. 
  • Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. 
  • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. 
  • Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. 
  • Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine. 
  • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. 
  • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. 
  • Improving peptide-MHC class I binding prediction for unbalanced datasets. 
  • In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. 
  • Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization. 
  • Intranasal Subunit Vaccination Strategies Employing Nanomaterials and Biomaterials. 
  • Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. 
  • Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis. 
  • Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. 
  • Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. 
  • Peptide vaccines for the treatment of glioblastoma. 
  • Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. 
  • Prospect of rindopepimut in the treatment of glioblastoma. 
  • Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. 
  • Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. 
  • Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. 
  • Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. 
  • Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. 
  • Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. 
  • Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation. 
  • Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. 
  • Supramolecular peptide vaccines: tuning adaptive immunity. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and Cryptococcal Species. 
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 
  • Vaccines in 2017: Closing in on a Zika virus vaccine. 
  • WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology